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Highlights 
 Twenty four percent of dogs affected with hypoadrenocorticism demonstrated 
autoantibodies against P450 side chain cleavage enzyme 
 The autoantibody status remained consistent in most dogs, but fluctuated in some 
animals 
 There was no relationship between autoantibody persistence and sex 
 
Abstract 
Autoantibodies directed against the P450 side chain cleavage enzyme (P450scc) have been 
recently described in dogs affected with hypoadrenocorticism, consistent with an immune-
mediated pathogenesis of this endocrinopathy. In human autoimmune Addison’s disease, 
autoantibodies may have a predictive value, being detectable before clinical signs developing, 
and have been shown to persist for a period of time after diagnosis. Furthermore, an 
autoantibody positive status post-diagnosis has been associated with successful remission of 
Addison’s disease following B-cell depletion, suggesting active immunopathology in these 
cases. The current study was designed to investigate changes in serum P450scc autoantibody 
status over time in dogs diagnosed with spontaneous hypoadrenocorticism. P450scc 
autoantibodies were measured using a species-specific radioimmunoprecipitation assay in an 
initial cohort of 213 dogs, indicating a prevalence of 24%. Thirty two of these dogs had 
repeat samples (n = 80 in total) available for analysis. Five dogs were consistently P450scc 
autoantibody positive in all samples, for up to 425 days following first sampling. Three dogs 
were initially autoantibody positive, then became seronegative at later time points. One dog, a 
1 year old female entire standard poodle, was initially negative for P450scc autoantibodies, 
but seroconverted 18 months after diagnosis.  The remaining 23 dogs with multiple samples 
available were consistently P450scc autoantibody negative. Persistence was not associated 
with sex (p = 0.673). This study demonstrates persistence of P450scc autoantibodies in a 
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subset of dogs affected with hypoadrenocorticism and seroconversion over one year post-
diagnosis. P450scc autoantibody reactivity in human autoimmune Addison’s disease has been 
associated with sex, with females having a higher prevalence, possibly due to P450scc 
expression in the ovary acting as an additional source of antigenic stimulation. However, 
there was no sex difference in autoantibody persistence in the dogs affected with 
hypoadrenocorticism. Autontibody persistence in dogs with hypoadrenocorticism might 
represent persistent pathology, due to residual antigenic stimulation and autoimmune 
inflammation in the adrenal gland. 
 
Keywords: Dog; Hypoadrenocorticism; Autoantibodies; Radioimmunoassay; Cholesterol 
side-chain cleavage enzyme; Addison’s disease 
 
1. Introduction 
Canine hypoadrenocorticism (Addison’s disease), caused by deficiency of corticosteroid 
hormones production by the adrenal gland, has important health and welfare implications ( 
Scott-Moncrieff, 2015). The condition can be challenging to diagnose due to the waxing and 
waning clinical signs that are not pathognomonic, including lethargy, anorexia, 
polyuria/polydipsia, vomiting and diarrhoea (Hughes et al., 2007; Peterson et al., 1996;; 
Thompson et al., 2007). Hypoadrenocorticism is diagnosed by ACTH stimulation test, 
demonstrating a deficiency in cortisol secretory capacity (Scott-Moncrieff, 2015). 
 
Adrenal glands histopathology from affected dogs indicates that a lymphocytic 
adrenalitis is present, followed by atrophy in end-stage disease (Adissu et al., 2010; Boujon et 
al., 1994; Frank et al., 2013; Hadlow, 1953; Schaer et al., 1986). These changes suggest an 
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autoimmune disorder analogous to human autoimmune Addison’s disease (AAD) (Betterle et 
al., 2002; Mitchell and Pearce, 2012). Genetic evidence supports an autoimmune 
pathogenesis for canine hypoadrenocorticism, with susceptibility linked to immune response 
genes including MHC class II, CTLA4 and PTPN22 (Boag and Catchpole, 2014; Chase et al., 
2006; Hughes et al., 2011; Hughes et al., 2010; Massey et al., 2013; Short et al., 2013; Short 
et al., 2014). 
 
Circulating autoantibodies are regarded as an important indicator of autoimmune 
disease (Blizzard and Kyle, 1963; Lleo et al., 2010; Rose and Bona, 1993), autoantibodies in 
human AAD patients have long been recognised (Anderson et al., 1957). The primary 
autoantigen in human AAD is 21-hydroxylase (21-OH), with specific autoantibodies present 
in 90% of patients at diagnosis and in approximately 50% of patients with longer standing 
disease (Bednarek et al., 1992; Betterle et al., 2005; Husebye and Løvås, 2009). A case report 
of a hypoadrenocorticoid dog with evidence of serum 21-OH autoantibodies has been 
recently published (Cartwright et al., 2016), although 21-OH autoantibodies were not 
identified in a larger cohort of affected dogs (Boag et al., 2015). In contrast, antibodies 
against the cytochrome P450 side-chain cleavage enzyme (P450scc) have been described in 
24% of dogs affected with hypoadrenocorticism (Boag et al., 2015), implicating an 
autoimmune-mediated pathogenesis in at least a proportion of cases. Autoantibodies against 
P450scc have also been described in human AAD, with the highest prevalence in female 
patients also affected with premature ovarian failure (POF), due to suspected autoimmune 
oophoritis (Betterle et al., 2005; Betterle et al., 1999; De Carmo Silva et al., 2000; Falorni et 
al., 2002; Pra et al., 2003). 
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The presence of adrenal autoantibodies has been shown to have a significant 
predictive role in a multivariate analysis of risk factors for development of human AAD 
(Betterle et al., 2005). In healthy humans that are positive for 21-OH autoantibodies, around 
15% will subsequently develop AAD within a six year period (Husebye and Løvås, 2009). 
Similarly, in a cohort of 234 thyroglobulin autoantibody (TGAA) positive dogs, 20% 
progressed within one year to demonstrate clinicopathological evidence of thyroid 
dysfunction (Graham et al., 2001). Autoantibodies are also associated with continued 
inflammatory or autoimmune processes and their persistence may indicate active disease in 
the adrenal gland. Autoantibody persistence has been shown to be associated with a worse 
clinical outcome and progressive disease in humans with latent autoimmune diabetes of 
adults (Huang et al., 2016) and with an increased risk of progressing to Type 1 diabetes 
mellitus in children, when compared to those with reversion of autoantibodies (Vehik et al., 
2016). Use of autoantibody status as a biomarker of active disease has been highlighted in a 
study showing clinical remission following B cell depletion, in a small open label pilot trial in 
humans with AAD, where one of the six patients was able to discontinue steroid therapy and 
had improved dynamic cortisol tests up to 27 months later (Pearce et al., 2012).  
 
Given the potential for autoantibody testing for diagnosis and monitoring of canine 
hypoadrenocorticism, the aim of the present study was to document P450scc autoantibody 
status in a cohort of dogs affected with hypoadrenocorticism, where repeat blood sampling 
had been undertaken. 
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2. Materials and methods 
2.1 Study population 
The study population consisted of 213 dogs affected with hypoadrenocorticism (Boag et al. 
2015). Residual serum samples were obtained following completion of diagnostic testing, 
undertaken either by the Royal Veterinary College (RVC) Diagnostic Service (Hatfield, UK) 
or NationWide Laboratories (Poulton-le-Fylde, UK). All sera included in the current study 
were from NationWide Laboratories.  
 
The Royal Veterinary College Institutional Ethics and Welfare Committee approved 
the use of residual blood samples, taken for diagnostic purposes, for research with informed 
owner consent. NationWide Laboratories has approval for utilising residual clinical samples 
for development of diagnostic assays, provided that UK data protection legislation is 
observed. 
 
2.2 Radioimmunoprecipitation assay 
The autoantibody assay was carried out as previously described (Boag et al., 2015). 
Briefly, radiolabelled recombinant P450scc protein (20,000 CPM radioactivity; 20 µL per 
reaction) diluted in IMP buffer (10 mM HEPES, 150 mM NaCl, 20 mM methionine, 10 mM 
benzamidine, 0.01 % BSA, 2.5 mL 0.5% Triton X-100; all Sigma–Aldrich, Poole, UK) was 
mixed with 10 µL serum in triplicate wells and incubated in V bottomed 96-well plates at 4 
°C for ~18 h. Opaque microtitre filter plates were blocked overnight with 100 µL/well of 2 
mg/mL BSA in phosphate-buffered saline (PBS) and washed twice with IMP buffer prior to 
use. Protein A sepharose (Sigma–Aldrich, Poole, UK) was added (10 l/well) and incubated 
with agitation for 20 min. The immunoprecipitate was transferred to wells of the filter plate 
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and washed with IMP buffer. Following drying, 100 µL/well MicroScint™ (Perkin Elmer, 
Cambridge, UK) was added and a Chameleon™ V plate reader (Hidex, Turku, Finland) used 
to quantify the amount of radioimmunoprecipitate. P450scc autoantibodies have been shown 
at both higher and lower dilutions and inter-assay coefficient of variation does not differ 
substantially with sample dilution; a representative example of dilutional parallelism is 
shown in supplementary figure 1. 
 
Relative autoantibody reactivity was calculated to allow inter-assay normalisation of 
data as follows: (CPMsample - CPMnegative_standard) / (CPMhigh_standard - CPMnegative_standard) × 100. 
The threshold value for autoantibody positivity was set at the mean + 3 × SD of controls (n = 
30) as previously described (Boag et al., 2015). 
 
2.3 Statistical analysis 
Statistical analyses were performed using SPSS© Statistics for Windows, version 20.0 (IBM 
Corp, Armonk, NY, USA). GraphPad Prism version 6.02 (GraphPad Software Inc., CA, 
USA) was used for construction of graphs. Categorical data were analysed using contingency 
tables, with Chi squared or Fisher’s exact test used for comparisons. Continuous data was 
tested for normality by manual inspection of histograms, Q-Q plots and Shapiro-Wilk (Razali 
and Wah, 2011). For normally distributed data, comparisons were made using two-sided 
unpaired Student’s t-tests, or ANOVA with post-hoc Bonferroni correction for multiple 
comparisons. Data not normally distributed were analysed using the Mann-Whitney U test or 
Kruskal-Wallis H test. Significance was accepted at p < 0.05.  
 
3. Results 
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Samples from 213 dogs were previously screened for P450scc autoantibodies, with a 
prevalence of 24% (Boag et al., 2015) . Within this cohort, 32 dogs had between two and six 
repeat blood samples, with 80 samples available overall; collected between two and 787 days 
from the first sample being taken. The mean time from diagnosis for all samples from dogs 
with a known date of diagnosis, was 200 days.  
 
Five dogs were consistently autoantibody positive in all samples analysed, up to 425 
days between sampling times, these comprised one male and four female dogs, and 3 dogs (a 
3 y 11 month old male entire bull terrier, a 4 y 5 month old female neutered beagle and a 2 y 
female entire crossbreed dog) were initially autoantibody positive, then became seronegative 
at later time points (Figure 1). One dog, a 1 y 8 month old female entire standard poodle, 
initially negative for P450scc autoantibodies, seroconverted 18 months after diagnosis 
(Figure 1). The remaining 23 dogs with multiple samples were consistently autoantibody 
negative (Table 1). Persistence of P450scc autoantibodies was not associated with sex (p = 
0.673). 
 
4. Discussion 
This study represents the first longitudinal analysis of autoantibody status in dogs affected 
with hypoadrenocorticism and reveals that autoantibody status varies between individual 
dogs and at different time points post-diagnosis. Five dogs remained autoantibody positive 
throughout the study period. Due to the short lived nature of antibodies without continued 
antigenic stimulation and plasma cell production, this could be explained by the presence of 
long lived plasma cells in these dogs, induced during the initial autoimmune process 
(Amanna and Slifka, 2010). Although lymphocytic adrenalitis typically leads to 
adrenocortical atrophy (Boujon et al., 1994; Frank et al., 2013), it is also possible that 
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residual adrenalitis can persist over a prolonged period, as previously described in one dog 
with long standing hypoadrenocorticism (9 years) which still had evidence of mild 
lymphoplasmacytic adrenalitis (Frank et al., 2013). In humans, plasma cells have been 
associated with the source of inflammation and persistence of autoantibodies in other immune 
mediated diseases including SLE and rheumatoid arthritis (Radbruch et al., 2006).  
Autoantibody persistence can be associated with a worse clinical outcome and disease 
progression in autoimmune endocrinopathy (Huang et al., 2016; Vehik et al., 2016), however 
detailed clinical data for the dogs in this study were not available due to the retrospective 
nature of the sample recruitment approach. 
 
The majority of dogs in this study (23/32) were initially, and remained, autoantibody 
negative. Since many of these samples were from dogs that had been diagnosed previously, 
an average of 200 days later, it is possible that there was a period of autoantibody positivity 
during the early stages of their autoimmune disease process and that these antibodies 
subsequently waned over time or that the immune focus in these cases is against another 
target in the adrenal gland such as 21-OH. Autoimmune destruction of the adrenal glands is 
thought to be a T cell-mediated process, and not all human patients are autoantibody positive 
(Husebye and Løvås, 2009). By comparison, in canine lymphocytic thyroiditis, prevalence 
estimates for TGAA are between 20-50%, with up to 85% reported in some breeds (Dixon 
and Mooney, 1999; Graham et al., 2007; Nachreiner et al., 1998; Patzl and Möstl, 2003). 
Whilst breed differences for P450scc autoantibodies are not particularly apparent, P450scc 
positivity does seem to be associated with DLA class II-type (Boag et al., 2015). Some of 
these dogs may not have had an autoimmune pathogenesis, neoplastic infiltration of the 
adrenal glands (Kook et al., 2010; Labelle and De Cock, 2005), infiltration with 
histoplasmosis (Frank et al., 2013) and bilateral abscessation have also been described (Korth 
AC
CE
PT
ED
 M
AN
US
CR
IPT
10 
et al., 2008) as relatively rare causes of primary hypoadrenocorticism. It is also possible that 
they had secondary hypoadrenocorticism, which is not associated with lymphocytic 
adrenalitis (Boujon et al., 1994; Peterson et al., 1996). 
 
Three dogs were initially P450scc autoantibody positive and reverted to autoantibody 
negative, which is commonly described in human AAD (Mitchell and Pearce, 2012). In dogs 
with lymphocytic thyroiditis, the likelihood of being TGAA positive at the time of diagnosis 
decreases with age, as does the autoantibody titre and those positive dogs can revert to being 
TGAA negative over time (Graham et al., 2007). This is likely due to diminished antigenic 
stimulation of B cells, following complete destruction of the endocrine tissue. This 
progression in the disease process, from early active inflammatory disease to atrophy of the 
organ (Table 2) has been suggested previously for hypothyroidism in dogs (Graham et al., 
2007) and Addison’s disease in humans (Mitchell and Pearce, 2012).  
 
One dog, a female entire standard poodle, seroconverted for P450scc autoantibodies 
over a year after diagnosis (as evidenced in two serum samples). This might be considered 
unexpected in the context of adrenal pathology, as most of the cortex is typically thought to 
be destroyed before the onset of clinical signs, thus removing the source of antigenic 
stimulation. This seroconversion could represent a reactivation of memory B cells, if the dog 
had been previously P450scc autoantibody positive before diagnosis. Since the dog was 
female entire, this might represent something similar to APS type 2 in humans, or progression 
to premature ovarian failure, with subsequent immune-mediated oophoritis. Since the ovary 
expresses the greatest amount of p450scc (Luu-The et al., 2005) this tissue would be the most 
likely source of p450scc antigenic stimulation in an animal with adrenocortical atrophy. 
Autoimmune oophoritis has been described in dogs (Nickel et al., 1991), although no 
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additional clinical information was available for this particular dog, to allow further 
investigation of this line of enquiry. Further investigation of reproductive parameters in 
female entire dogs affected with hypoadrenocorticism is clearly warranted. Since a large 
proportion of dogs are routinely neutered and female entire dogs affected with 
hypoadrenocorticism are not usually used for breeding purposes, this could be an under-
reported endocrinopathy (O’Neill et al., 2013). 
 
The study was designed as a longitudinal cohort study with passive sample 
recruitment, which meant that there was no control over the cases from which samples were 
available, nor when those samples were taken by veterinary surgeons during routine 
monitoring and diagnostics. Therefore the time between first and last samples was somewhat 
short for some cases and, not surprisingly, no change in autoantibody status was observed. 
However, the lack in change over such short time periods in these cases, increases the 
confidence in the biological validity of the autoantibody assay and therefore strengthens the 
conclusions regarding persistence, reversion and seroconversion in other cases. A further 
limitation imposed by the sample collection strategy and availability of patient data (while 
conforming with UK data protection legislation), is the absence of case detail, regarding the 
course of the clinical disease in these dogs. 
 
This study is the first to undertake a longitudinal assessment of P450scc autoantibody 
status in canine hypoadrenocorticism and demonstrates individual variability in persistence, 
reversion and seroconversion. Whilst P450scc autoantibodies are more prevalent in affected 
female dogs (Boag et al., 2015), there was no significant association between sex and 
persistence. Further work is required in a larger number of dogs to determine whether the 
presence of P450scc autoantibodies is associated with reproductive dysfunction in affected 
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female dogs and whether measurement of circulating P450scc autoantibodies could be of use 
as part of the diagnostic approach for canine hypoadrenocorticism. Furthermore, 
autoantibody status of a more rigorously phenotyped population would allow autoantibody 
status and disease severity or progression to be assessed.  
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Table 1. Signalment and sample information for dogs persistently P450scc autoantibody 
negative. Sex defined as male (M) or female (F) followed by neuter status entire (E), neutered 
(N) or unknown (U). 
 
Breed Sex 
Number of 
samples 
Days between first and last 
samples 
Rottweiler MN 2 2 
West Highland white 
terrier 
MN 3 22 
Labradoodle FN 4 34 
Crossbreed FN 2 787 
Cocker spaniel MU 2 42 
Standard poodle MN 2 56 
Weimaraner FU 2 13 
Portuguese water dog MU 3 111 
Springer spaniel FU 2 19 
Staffordshire bull terrier FE 2 37 
Border collie MN 2 2 
Springer spaniel FU 3 158 
Bearded collie MN 3 26 
Standard poodle FE 2 2 
West Highland white 
terrier 
FU 2 109 
Labradoodle FN 3 354 
Springer spaniel FN 3 63 
Staffordshire bull terrier FE 2 294 
Crossbreed FN 2 380 
Standard poodle MN 2 361 
Border collie FU 2 6 
Crossbreed ME 6 544 
Crossbreed MN 2 69 
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Table 2. General hypothetical model of autoimmune disease progression (adapted from 
Graham 2007 and Mitchell and Pearce 2012) 
 
Stage Pathology Autoantibodies Clinical picture 
1 
Focal lymphocytic 
infiltration 
Negative (antigen 
release) 
Normal 
2 
Fully developed 
lymphocytic infiltration 
Positive Subclinical disease 
3 
Majority of the target 
organ destroyed 
Positive to negative Overt disease 
4 Atrophic gland Negative Overt disease 
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FIGURE LEGEND 
Figure 1. p450scc autoantibody status over time. Time from first sample is on the x axis 
(days) and P450scc autoantibody reactivity, as measured by radioimmunoprecipitation.assay, 
on the y axis. The dotted line represents the threshold for positivity (mean + 3×SD of control 
sera).  Dogs signalment was as follows; Dog1: FE poodle; Dog 2: ME bull terrier; Dog 3: FN 
beagle; Dog 4: FE crossbreed ; Dog 5: ME English springer spaniel; Dog 6: FU Dogo 
Argentino; Dog 7: FN crossbreed; Dog 8: FN crossbreed; Dog 9: FN Crossbreed. Sex defined 
as male (M) or female (F) followed by neuter status entire (E), neutered (N) or unknown (U). 
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